Since MEK1 is a proto‐oncogene, and inhibitors of MEK1 are standard‐of‐care for the treatment of certain cancers, we expected MEK1 overexpression in tumour cells might increase their growth rate. This evidence concerns the gene MAP2K1 and neoplasm.